This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings declined year over year but revenues increased on a year-over-year basis. The company remains focused on launching new products.
Novartis Buys French Radiopharmaceutical Company
by Zacks Equity Research
Novartis (NVS) plans to acquire France-based Advanced Accelerator Applications. The takeover will add RadioLigand Therapy, Lutathera, in its portfolio with potential to drive growth in the near term.
Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View
by Zacks Equity Research
Alkermes' (ALKS) earnings beat estimates but sales lagged the same in the third quarter of 2017.
Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Down Y/Y
by Zacks Equity Research
Bayer AG's (BAYRY) core earnings per share from continuing operations beat expectations in the third quarter of 2017 and the company lost de facto control over the Covestro Group at the end of the quarter.
Alexion (ALXN) Tops Q3 Earnings, Lags Sales, 2017 View Up
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.???s (ALXN) beat earnings estimates but missed sales estimates in the third quarter of 2017.
United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat
by Zacks Equity Research
United Therapeutics' (UTHR) earnings grow year over year in the third quarter of 2017. Revenues too surpass estimates in the reported quarter.
Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics
by Zacks Equity Research
AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.
Novartis Reports Positive Results on Thrombocytopenia Drug
by Zacks Equity Research
Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.
Impax Laboratories and Amneal Pharmaceuticals Agree to Merge
by Zacks Equity Research
Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
by Zacks Equity Research
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
Shire's New Formulation of Oncaspar Gets CHMP Recommendation
by Zacks Equity Research
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.
AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge
by Zacks Equity Research
AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.
Ligand (LGND) Signs Deal to Acquire Crystal Bioscience
by Zacks Equity Research
Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash.
Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Palatin Technologies (PTN) in Focus: Stock Moves 13.2% Higher
by Zacks Equity Research
Palatin Technologies (PTN) was a big mover last session, as the company saw its shares rise more than 13% on the day.
Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher
by Zacks Equity Research
Catabasis Pharmaceuticals (CATB) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.
MannKind (MNKD) in Focus: Stock Moves 7.8% Higher
by Zacks Equity Research
MannKind (MNKD) shares rose nearly 8% in the last trading session, amid huge volumes.
Ligand's Captisol Deals Set to Drive Growth in the Long Run
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.
Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Ligand Pharma (LGND)
by David Bartosiak
Drug stocks have become very hot lately and this off-the-radar name may soon be a big hit
Ascendis Pharma (ASND) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
Ascendis Pharma (ASND) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher
by Zacks Equity Research
Aimmune Therapeutics (AIMT) shares rose more than 6% in the last trading session, amid huge volumes.
Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day
3 Healthcare Stocks to Buy on Renewed Obamacare Repeal Talks
by Benjamin Rains
Healthcare has been a newsworthy topic for decades, and that is unlikely to cease anytime soon as the Republican effort to repeal and replace the Affordable Care Act, or Obamacare, ramps up ahead of a key Sept. 30 deadline.